---

Abstract Background and objectives: Genital tract infections are among the most common causes of patients referred to therapeutic centers. Nearly 75% of women suffer from genital Candida infection, at least once in their lifetime. The aim of present study was detection of Candida species causing vaginitis and the evaluation of antimycotic effects of ketoconazol, clotrimazole and fluconazole against Candida species. Material and Methods: In this study, 210 vaginal samples were obtained from the patients suspected of Vaginal Candidiasis. Direct examination and culture were carried out for all specimens to detect the yeast. The isolated yeast species were then identified, using various different tests such as culture on corn meal agar, tween-80, germ tube test, and assimilation test by API 20C kit by using Sabouraud Dextrose Agar and microdilution broth, MIC90 and MIC50 of drug were measured and determined their drug resistance. Results: In the present study, 100 yeast colonies were isolated from patients %80 are C. albicans and the rest are C. parapsilosis(2%), C. tropicalis(6%), C. glabrata(4%), C. krusei(2%), C. guilliermondii (3%), C.stellatoidea(3%). In terms of drug resistance test MIC50 and MIC90 of fluconazole for candida albicans are 5.33 and 35.27μg/ ml, respectively, and for non-albicans candida are 3 and 21.4μg/ml, respectively. Clotrimazole MIC for Candida albicans (MIC50, MIC90) 0.97 and 4.9μg/ml, respectively, and for non-albicans 0.63 and 3.4/ml, respectively. Kectoconazole MIC for Candida albicans 2.43 and 16.45μg/ml, respectively, and for non-albicans 1.12 and 6.6μg/ml, respectively. Conclusion: Clotrimazole has been better than the two other drugs for Candida species on the whole, non albicans species are more sensitive than albicans species in the presence of the drugs used in this study. Key words: Candida, vaginal candidiasis, Resistance drug , Tonekabon.

---

Background: Vulvovaginal candidiasis (VVC) remains one of the most common infections of the female genital tract. This local study was conducted to identify the spectrum of Candida species associated with VVC and recurrent vulvovaginal candidiasis (RVVC) using different phenotypic and genotypic methods and assess their fluconazole susceptibility.
Methods: High vaginal swabs were collected from 576 patients with VVC. Swabs were subjected to KOH 10% and cultured on Sabouraud dextrose agar. The species identification of Candida isolates was made using phenotypic methods, including the germ tube test, corn meal agar (CMA), CHROMagar Candida, and PCR-RFLP as the best genotypic methods for confirmation of Candida species in vulvovaginal candidiasis. Fluconazole susceptibility testing was performed using the disk diffusion method.
Results: The data were analyzed using the chi-square test. The prevalence of candidiasis was 61%. The socio-demographic profile corresponded to a woman aged 29.14 ± 4.8 years on average, pregnant (77%), diabetic (19%), with hypertension (10%), recurrent (9%), a history of fluconazole use (4%), and under 30 years of age (73%).
Vaginal swab cultures yielded Candida growth in 352 cases (61%). Candida albicans was the predominant isolated species (78%), while the most common non-albicans species were C. glabrata (14.7%), C. parapsilosis (4.2%), C. tropicalis (2.8%), and C. krusei (0.56%). Isolates of C. glabrata and C. krusei exhibited the highest rate of DDS resistance among all isolates tested.
Conclusion: C. albicans was the most common species. Careful periodical surveillance is needed to identify any changes in the susceptibility patterns to fluconazole with the increased use of this antifungal agent in Sayad Shirazi tertiary care hospital, Iran.